|
|
Des-gamma-carboxy prothrombin is a promising biomarker of hepatocellular carcinoma and a predictor of complications in patients with chronic liver diseases |
Lan-Yue Pan a , Xiao-Meng Hu b , Peng Han c , Dao-Feng Yang a , ∗ |
a Department and Institute of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030,
China
b Tuberculosis IV Ward, Wuhan Pulmonary Hospital, Wuhan 430030, China
c Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
∗ Corresponding author.
E-mail address: yangdaofeng@tjh.tjmu.edu.cn (D.-F. Yang). |
|
|
Abstract Although des-gamma-carboxy prothrombin (DCP) is considered a complementary biomarker to alpha-fetoprotein (AFP) in the diagnosis of hepatocellular carcinoma (HCC), its cut-off value has not been recommended in any guideline. This study aimed to explore the diagnostic efficacy of DCP on HCC.
|
|
|
|
|
|
|
|